Prognostic Factors and Treatment Outcomes for Early-Stage Hodgkin Lymphoma in Cape Town, South Africa - Takeaways - MDSpire

Prognostic Factors and Treatment Outcomes for Early-Stage Hodgkin Lymphoma in Cape Town, South Africa

  • By

  • Shakira Dawood

  • Brigid McMillan

  • Karryn Brown

  • Jenna Oosthuizen

  • David Richardson

  • Kudakwashe Simba

  • Lillian F. Andera

  • Jessica Opie

  • Katherine Antel

  • Stuart More

  • Ayesha Allie

  • Zainab Mohamed

  • Estelle Verburgh

  • November 25, 2025

  • 0 min

Share

  • 1

    Classic Hodgkin lymphoma (cHL) has a global incidence of 1–3 per 100,000 individuals, with a significantly higher risk in people living with HIV.

  • 2

    In South Africa, only 13%–18% of cHL patients are diagnosed at early stages, compared to 52%–59% in the United States, leading to poorer outcomes.

  • 3

    Diagnostic delays in South Africa are exacerbated by overlapping symptoms with tuberculosis, resulting in advanced disease at diagnosis.

  • 4

    The study aimed to evaluate progression-free survival and overall survival in early-stage cHL patients treated at Groote Schuur Hospital.

  • 5

    Patients received treatment based on NCCN and ESMO guidelines, adapted for local resources, with a focus on combined modality or chemotherapy-only approaches.

Original Source(s)

Prognostic Factors and Treatment Outcomes for Early-Stage Hodgkin Lymphoma in Cape Town, South Africa

  • by Shakira Dawood, Brigid McMillan, Karryn Brown, Jenna Oosthuizen, David Richardson, Kudakwashe Simba, Lillian F. Andera, Jessica Opie, Katherine Antel, Stuart More, Ayesha Allie, Zainab Mohamed, Estelle Verburgh

  • November 25, 2025

Related Content

Epstein-Barr virus associated diseases: Immune alterations and targeted approaches

Case Report: Extranodal marginal zone B-cell lymphoma in the lateral ventricle: literature review

Advances in Hodgkin Lymphoma Treatment: Clinical Considerations for Managing Toxicities in Nivolumab-AVD Therapy

One of the most promising developments in advanced-stage Hodgkin lymphoma is the nivolumab-AVD regimen, which combines nivolumab with doxorubicin, vinblastine, and dacarbazine. This article provides practical knowledge for advanced practitioners to effectively manage the most common toxicities associated with nivolumab-AVD.